Dr. Scott R. Checketts, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Geisel School of Medicine at Dartmouth (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 442
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Geisel School of Medicine at Dartmouth
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
UT license 2772391205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Tanner Memorial Clinic (245 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 442
- Services billed
- 1,412
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 384 | 81 |
| Established patient office or other outpatient visit, 20-29 minutes | 292 | 237 |
| Pathology examination of tissue using a microscope, intermediate complexity | 226 | 151 |
| Destruction of skin growth, 1-14 growths | 126 | 114 |
| Destruction of precancer skin growth, 1 growth | 121 | 98 |
| New patient office or other outpatient visit, 15-29 minutes | 115 | 115 |
| Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 35 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 24 | 23 |
| Biopsy of related skin growth, first growth | 22 | 22 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 21 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobetasol Propionate Other prescribers in Layton, UT | 96 |
| Finasteride Other prescribers in Layton, UT | 64 |
| Triamcinolone Acetonide Other prescribers in Layton, UT | 61 |
| Ketoconazole Other prescribers in Layton, UT | 35 |
| Minocycline Hcl Other prescribers in Layton, UT | 25 |
| Prednisone Other prescribers in Layton, UT | 22 |
| Terbinafine Hcl Other prescribers in Layton, UT | 21 |
| Cephalexin Other prescribers in Layton, UT | 18 |
| Cyclosporine Modified (cyclosporine, modified) | 15 |
| Doxycycline Hyclate Other prescribers in Layton, UT | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 11 payments worth $187 in total to this clinician.
| Janssen Biotech, Inc. | $75.00 |
|---|---|
| Leo Pharma Inc. | $29.00 |
| Organon LLC | $26.59 |
| Almirall LLC | $23.50 |
| Amgen Inc. | $18.52 |
| AbbVie Inc. | $14.17 |
| Food and Beverage | $112 |
|---|---|
| Education | $75.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jul 14, 2025 | Education TREMFYA · Immunology · in-kind | $75.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $150,631 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sanofi US Services Inc. · Completed · NCT06224348 - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A phase 4, prospective, open-label, single arm study to assess the effectiveness of tirzepatide after initiation of ixekizumab in adult participants with moderate-to-severe plaque psoriasis and obesity or overweight i…
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.